Literature DB >> 12910363

External beam radiation therapy: role of androgen deprivation.

Patrick Kupelian1.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12910363     DOI： 10.1007/s00345-003-0355-y

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  36 in total

1.  Short-course, intensity-modulated radiotherapy for localized prostate cancer.

Authors:  P A Kupelian; T R Willoughby
Journal:  Cancer J       Date:  2001 Sep-Oct       Impact factor: 3.360

2.  Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation.

Authors:  D L Joon; M Hasegawa; C Sikes; V S Khoo; N H Terry; G K Zagars; M L Meistrich; A Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-07-15       Impact factor: 7.038

3.  Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy.

Authors:  G E Hanks; A L Hanlon; W H Pinover; E M Horwitz; T E Schultheiss
Journal:  Cancer J Sci Am       Date:  1999 May-Jun

4.  Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10).

Authors:  P A Kupelian; J C Buchsbaum; C A Reddy; E A Klein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

5.  Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer.

Authors:  A A Martinez; D Yan; D Lockman; D Brabbins; K Kota; M Sharpe; D A Jaffray; F Vicini; J Wong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-08-01       Impact factor: 7.038

6.  Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation.

Authors:  G K Zagars; A Pollack; A C von Eschenbach
Journal:  Cancer       Date:  1997-08-15       Impact factor: 6.860

7.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

8.  Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.

Authors:  M S Soloway; R Sharifi; Z Wajsman; D McLeod; D P Wood; A Puras-Baez
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

9.  Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.

Authors:  William A See; Manfred P Wirth; David G McLeod; Peter Iversen; Ira Klimberg; Donald Gleason; Gerald Chodak; James Montie; Chris Tyrrell; D M A Wallace; Karl P J Delaere; Sigmund Vaage; Teuvo L J Tammela; Olavi Lukkarinen; Bo-Eric Persson; Kevin Carroll; Geert J C M Kolvenbag
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

10.  Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

Authors:  M J Zelefsky; S A Leibel; P B Gaudin; G J Kutcher; N E Fleshner; E S Venkatramen; V E Reuter; W R Fair; C C Ling; Z Fuks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-06-01       Impact factor: 7.038
View more
  1 in total

1.  Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer.

Authors:  Yu Jin Kang; Ki Ho Kim; Kyung Seop Lee
Journal:  Korean J Urol       Date:  2014-05-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.